Back to Search Start Over

Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent

Authors :
Jost, Marco
Chen, Yuwen
Gilbert, Luke A
Horlbeck, Max A
Krenning, Lenno
Menchon, Grégory
Rai, Ankit
Cho, Min Y
Stern, Jacob J
Prota, Andrea E
Kampmann, Martin
Akhmanova, Anna
Steinmetz, Michel O.
Tanenbaum, Marvin E
Weissman, Jonathan S
Sub Cell Biology
Celbiologie
Hubrecht Institute for Developmental Biology and Stem Cell Research
Sub Cell Biology
Celbiologie
Source :
Molecular Cell, 68(1), 210. Cell Press, Molecular Cell, Molecular Cell, 68(1), 210-223.e6. Cell Press, Molecular cell, vol 68, iss 1

Abstract

Summary Chemical libraries paired with phenotypic screens can now readily identify compounds with therapeutic potential. A central limitation to exploiting these compounds, however, has been in identifying their relevant cellular targets. Here, we present a two-tiered CRISPR-mediated chemical-genetic strategy for target identification: combined genome-wide knockdown and overexpression screening as well as focused, comparative chemical-genetic profiling. Application of these strategies to rigosertib, a drug in phase 3 clinical trials for high-risk myelodysplastic syndrome whose molecular target had remained controversial, pointed singularly to microtubules as rigosertib’s target. We showed that rigosertib indeed directly binds to and destabilizes microtubules using cell biological, in vitro, and structural approaches. Finally, expression of tubulin with a structure-guided mutation in the rigosertib-binding pocket conferred resistance to rigosertib, establishing that rigosertib kills cancer cells by destabilizing microtubules. These results demonstrate the power of our chemical-genetic screening strategies for pinpointing the physiologically relevant targets of chemical agents.<br />Graphical Abstract<br />Highlights • Combined CRISPRi/a chemical-genetic screening reveals targets of therapeutic agents • Focused chemical-genetic profiling rapidly classifies agents by mechanism of action • Chemical-genetic screens with rigosertib reveal a microtubule-destabilizing signature • Targeted in vivo and in vitro approaches confirm rigosertib’s mechanism of action<br />Jost et al. present a two-tiered strategy to identify molecular targets of bioactive compounds using CRISPRi/a-mediated chemical-genetic screens. Application to rigosertib, an anti-cancer drug with an unclear mechanism of action, points to rigosertib being a microtubule-destabilizing agent. Targeted cell biological, biochemical, and structural approaches confirm this mechanism of action.

Details

Language :
English
ISSN :
10972765
Volume :
68
Issue :
1
Database :
OpenAIRE
Journal :
Molecular Cell
Accession number :
edsair.doi.dedup.....f179af91573489aafc58613822af4048
Full Text :
https://doi.org/10.1016/j.molcel.2017.09.012